Investment Analysts’ Recent Ratings Changes for NewAmsterdam Pharma (NAMS)

A number of research firms have changed their ratings and price targets for NewAmsterdam Pharma (NASDAQ: NAMS):

• 2/21/2026 – NewAmsterdam Pharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/19/2026 – NewAmsterdam Pharma had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 2/19/2026 – NewAmsterdam Pharma had its price target raised by Guggenheim from $41.00 to $45.00. They now have a “buy” rating on the stock.
• 2/19/2026 – NewAmsterdam Pharma was upgraded by HC Wainwright to “strong-buy”.
• 2/18/2026 – NewAmsterdam Pharma had its price target raised by Needham & Company LLC from $46.00 to $48.00. They now have a “buy” rating on the stock.
• 1/22/2026 – NewAmsterdam Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/21/2026 – NewAmsterdam Pharma had its price target raised by Royal Bank Of Canada from $44.00 to $47.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In other news, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the sale, the chief executive officer owned 174,144 shares in the company, valued at $5,790,288. This represents a 71.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 45,481 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $35.31, for a total value of $1,605,934.11. Following the completion of the sale, the insider directly owned 53,500 shares of the company’s stock, valued at approximately $1,889,085. The trade was a 45.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,094,128 shares of company stock valued at $37,170,889 in the last 90 days. 20.84% of the stock is currently owned by insiders.

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.